Publications by authors named "Saad Z Usmani"

100Publications

Defining and Managing High-Risk Multiple Myeloma: Current Concepts.

J Natl Compr Canc Netw 2020 12 2;18(12):1730-1737. Epub 2020 Dec 2.

2Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.

View Article and Find Full Text PDF
December 2020

Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2020 Sep 18. Epub 2020 Sep 18.

Plasma Cell Disorders Division, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.

View Article and Find Full Text PDF
September 2020

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.

Bone Marrow Transplant 2021 Jan 7;56(1):9-19. Epub 2020 Aug 7.

BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.

View Article and Find Full Text PDF
January 2021

Daratumumab subcutaneous formulation for the treatment of multiple myeloma.

Expert Opin Biol Ther 2020 Nov 16;20(11):1253-1259. Epub 2020 Aug 16.

Division of Plasma Cell Disorders, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health , Charlotte, NC, USA.

View Article and Find Full Text PDF
November 2020

Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.

Lancet Haematol 2020 08;7(8):e559

Levine Cancer Institute-Atrium Health, Charlotte, NC 28204, USA. Electronic address:

View Article and Find Full Text PDF
August 2020

Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.

Clin Lymphoma Myeloma Leuk 2020 Oct 7;20(10):e777-e781. Epub 2020 Jun 7.

Department of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC.

View Article and Find Full Text PDF
October 2020

An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.

Expert Rev Hematol 2020 Aug 20;13(8):795-802. Epub 2020 Sep 20.

Division of Plasma Cell Disorders, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health , Charlotte, NC, USA.

View Article and Find Full Text PDF
August 2020

Management of newly diagnosed transplant ineligible multiple myeloma.

Leuk Lymphoma 2020 11 4;61(11):2549-2560. Epub 2020 Jul 4.

Department of Hematologic Oncology & Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.

View Article and Find Full Text PDF
November 2020

Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol.

Clin Lymphoma Myeloma Leuk 2020 Aug 7;20(8):526-532.e1. Epub 2020 Mar 7.

Plasma Cell Disorders Division, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC. Electronic address:

View Article and Find Full Text PDF
August 2020

Extramedullary Disease in Multiple Myeloma.

Curr Hematol Malig Rep 2020 04;15(2):62-71

Plasma Cell Disorders, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health UNC School of Medicine, Charlotte, NC, USA.

View Article and Find Full Text PDF
April 2020

Quadruplets come of age for newly diagnosed multiple myeloma.

Lancet 2020 01 10;395(10218):94-96. Epub 2019 Dec 10.

Division of Plasma Cell Disorders, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute-Atrium Health, Charlotte, NC 28204, USA. Electronic address:

View Article and Find Full Text PDF
January 2020

Extramedullary multiple myeloma.

Leukemia 2020 01 27;34(1):1-20. Epub 2019 Nov 27.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.

View Article and Find Full Text PDF
January 2020

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article and Find Full Text PDF
May 2019

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e176-e186. Epub 2019 May 17.

4 Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.

View Article and Find Full Text PDF
January 2019

Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.

Leuk Lymphoma 2019 09 8;60(9):2295-2298. Epub 2019 Mar 8.

Department of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute , Charlotte , NC , USA.

View Article and Find Full Text PDF
September 2019

Treatment approach for young, fit, newly diagnosed multiple myeloma patients.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):97-102

Johns Hopkins University School of Medicine, Baltimore, MD.

View Article and Find Full Text PDF
November 2018

Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.

J Oncol Pharm Pract 2019 Jun 26;25(4):1021-1025. Epub 2018 Nov 26.

2 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

View Article and Find Full Text PDF
June 2019

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

Front Immunol 2018 20;9:2134. Epub 2018 Sep 20.

Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, United States.

View Article and Find Full Text PDF
October 2019

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Drug Des Devel Ther 2017 20;11:893-900. Epub 2017 Mar 20.

Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA.

View Article and Find Full Text PDF
May 2017

Practical Considerations in Managing Relapsed Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2017 02 23;17(2):69-77. Epub 2016 Nov 23.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC. Electronic address:

View Article and Find Full Text PDF
February 2017

The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.

Expert Rev Hematol 2016 Dec 14;9(12):1177-1187. Epub 2016 Nov 14.

a Department of Hematologic Oncology and Blood Disorders , Levine Cancer Institute/Carolinas HealthCare System , Charlotte , NC , USA.

View Article and Find Full Text PDF
December 2016

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article and Find Full Text PDF
October 2016

Maintenance lenalidomide after transplantation: How much is enough?

Authors:
Saad Z Usmani

Cancer 2016 12 28;122(24):3762-3764. Epub 2016 Sep 28.

Levine Cancer Institute/Carolinas Healthcare System, Charlotte, North Carolina.

View Article and Find Full Text PDF
December 2016

The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.

Clin Adv Hematol Oncol 2016 Sep;14(9):719-28

Levine Cancer Institute of the Carolinas HealthCare System, Charlotte, North Carolina.

View Article and Find Full Text PDF
September 2016

Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders.

Semin Oncol 2016 06 23;43(3):395-400. Epub 2016 Feb 23.

Plasma Cell Disorders Program, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC. Electronic address:

View Article and Find Full Text PDF
June 2016

Successful Treatment of Hepatitis C Infection While Receiving Concurrent Chemotherapy for AL Amyloidosis.

Clin Lymphoma Myeloma Leuk 2016 Apr 18;16(4):237-9. Epub 2016 Jan 18.

Department of Hematologic Oncology and Blood Disorders, Carolinas HealthCare System, Levine Cancer Institute, Charlotte, NC.

View Article and Find Full Text PDF
April 2016

Multiple myeloma: is it time for biomarker-driven therapy?

Am Soc Clin Oncol Educ Book 2015 :e493-503

From the Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article and Find Full Text PDF
February 2016

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Clin Case Rep 2015 Mar 13;3(3):183-92. Epub 2015 Feb 13.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.

View Article and Find Full Text PDF
March 2015

Novel drug combinations for the management of relapsed/refractory multiple myeloma.

Clin Lymphoma Myeloma Leuk 2014 Sep;14 Suppl:S71-7

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Electronic address:

View Article and Find Full Text PDF
September 2014

Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.

Semin Hematol 2014 Jan 15;51(1):73-86. Epub 2013 Nov 15.

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute and University of South Florida College of Medicine, Tampa, FL.

View Article and Find Full Text PDF
January 2014

Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.

Clin Lymphoma Myeloma Leuk 2014 Jun 16;14(3):211-4. Epub 2013 Nov 16.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR. Electronic address:

View Article and Find Full Text PDF
June 2014

Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.

Clin Cancer Res 2013 Nov 27;19(22):6242-51. Epub 2013 Sep 27.

Authors' Affiliations: Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina; Levine Cancer Institute, Charlotte, North Carolina; Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York; and The University of Texas MD Anderson Cancer Center, Texas.

View Article and Find Full Text PDF
November 2013

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

PLoS One 2013 16;8(9):e74191. Epub 2013 Sep 16.

Myeloma Institute for Research and Therapy, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

View Article and Find Full Text PDF
May 2014

Melphalan continues to rock the myeloma world.

Authors:
Saad Z Usmani

Biol Blood Marrow Transplant 2013 May 24;19(5):680-1. Epub 2013 Feb 24.

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article and Find Full Text PDF
May 2013

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

Blood 2013 Mar 10;121(10):1819-23. Epub 2013 Jan 10.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article and Find Full Text PDF
March 2013

Thalidomide and its analogues in the treatment of Multiple Myeloma.

Exp Hematol Oncol 2012 Sep 11;1(1):27. Epub 2012 Sep 11.

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, 4301 W, Markham Street, Little Rock, AR, USA.

View Article and Find Full Text PDF
September 2012